[Placenta Growth Factor (PlGF) and Retinal Vascular Diseases--Current Knowledge from Experimental and Clinical...

Area of Science:

• Ophthalmology
• Vascular Biology
• Oncology

Background:

• Pathological angiogenesis underlies major diseases including cancer and retinal vascular disorders.
• Diabetic retinopathy (DR) and neo-vascular age-related macular degeneration (nAMD) are leading causes of vision loss, driven by abnormal blood vessel growth.
• While VEGF-A is a known target, placental growth factor (PlGF) is emerging as a critical factor in pathological angiogenesis.

Purpose of the Study:

• To review the role of placental growth factor (PlGF) in retinal vascular diseases.
• To summarize experimental data on the therapeutic potential of PlGF inhibitors for these conditions.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the expression and function of PlGF in pathological angiogenesis.
• Evaluation of therapeutic strategies targeting PlGF.

Main Results:

• PlGF expression is significantly upregulated in pathological conditions like retinal vascular diseases, unlike in healthy tissues.
• Preclinical studies and clinical trials in oncology show promising results for PlGF inhibition.
• Targeting PlGF may offer a more specific antiangiogenic therapy, potentially sparing healthy tissues.

Conclusions:

• PlGF is a crucial mediator of pathological angiogenesis in retinal vascular diseases.
• Inhibitors of PlGF represent a promising therapeutic avenue for treating DR and nAMD.
• Targeted PlGF inhibition could expand treatment options for vision-threatening retinal vascular disorders.